Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Marc Agronin, MD, presents an interactive case study involving an 88-year-old woman diagnosed with Alzheimer disease and living in a nursing home showing symptoms of agitation, irritability, and paranoia. Read the case, share how you would proceed, and watch Dr Agronin discuss how he would treat this patient.
In this podcast, Rakesh Jain, MD, MPH, examines the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
In this podcast, Rakesh Jain, MD, MPH, examines the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
Listen to a discussion on the importance of sleep in the production of body homeostasis and the glymphatic system's ability to drain buildup of toxins in the brain.
Listen to a discussion on the importance of sleep in the production of body homeostasis and the glymphatic system's ability to drain buildup of toxins in the brain.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with C. Debbie Lin, MD, discussing some of the major challenges in neurology private practice, balancing work with other aspects of her life, and the career advice...
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with C. Debbie Lin, MD, discussing some of the major challenges in neurology private practice, balancing work with other aspects of her life, and the career advice...
In this episode, Rachel Marie E. Salas, MD, MEd, talks with with C. Debbie Lin, MD, to discuss why she pursued private practice and the excitement she finds in practicing as a general neurologist.
In this episode, Rachel Marie E. Salas, MD, MEd, talks with with C. Debbie Lin, MD, to discuss why she pursued private practice and the excitement she finds in practicing as a general neurologist.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Mark J. Milstein, MD, FAAN, to discuss how he discovered his interest in medical education and future trends in neurology training.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Mark J. Milstein, MD, FAAN, to discuss how he discovered his interest in medical education and future trends in neurology training.
In this episode, Rachel Marie E. Salas, MD, MEd, wraps up her conversation with Mark J. Milstein, MD, FAAN, with details on his advocacy work through the American Medical Association and the American Academy of Neurology, and how neurologists...
In this episode, Rachel Marie E. Salas, MD, MEd, wraps up her conversation with Mark J. Milstein, MD, FAAN, with details on his advocacy work through the American Medical Association and the American Academy of Neurology, and how neurologists...
In this episode, Rachel Marie E. Salas, MD, MEd, talks with Mark J. Milstein, MD, FAAN, to discuss his hybrid clinical work as a neurohospitalist and neuromuscular specialist at Montefiore Medical Center in the Bronx, New York.
In this episode, Rachel Marie E. Salas, MD, MEd, talks with Mark J. Milstein, MD, FAAN, to discuss his hybrid clinical work as a neurohospitalist and neuromuscular specialist at Montefiore Medical Center in the Bronx, New York.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Madhu Mona Soni, MD, FAAN, to discuss future trends in neurology, wellness in the workplace, and telehealth.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Madhu Mona Soni, MD, FAAN, to discuss future trends in neurology, wellness in the workplace, and telehealth.
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Rachel Marie E. Salas, MD, MEd, interviews Marie Eugene, DO, about her work in medical education and training, what being an epilepsy specialist involves, and new developments in epileptology.
In this episode, Rachel Marie E. Salas, MD, MEd, interviews Marie Eugene, DO, about her work in medical education and training, what being an epilepsy specialist involves, and new developments in epileptology.
Are you up-to-date on the most recent recommendations for managing antiseizure medications in people with epilepsy of childbearing potential? Take this short, 2-part quiz to refresh your understanding of the evidence-based guidelines.
Are you up-to-date on the most recent recommendations for managing antiseizure medications in people with epilepsy of childbearing potential? Take this short, 2-part quiz to refresh your understanding of the evidence-based guidelines.
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
Comorbid ADHD is common in people with Tourettes syndrome (TS), with what range of prevalence? In children with tics and ADHD, what treatment does not worsen tics and reduces ADHD symptoms? Find out!
Comorbid ADHD is common in people with Tourettes syndrome (TS), with what range of prevalence? In children with tics and ADHD, what treatment does not worsen tics and reduces ADHD symptoms? Find out!
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
The second annual Neurology Week virtual education experience recently convened from September 7th through 10th for 4 days of practical education from leading minds in the neurology field.
The second annual Neurology Week virtual education experience recently convened from September 7th through 10th for 4 days of practical education from leading minds in the neurology field.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Amrou Sarraj, MD, interviews Dileep R Yavagal, MD, about the efforts of Mission Thrombectomy 2020+ and their efforts to implement 202,000 thrombectomies globally.
Amrou Sarraj, MD, interviews Dileep R Yavagal, MD, about the efforts of Mission Thrombectomy 2020+ and their efforts to implement 202,000 thrombectomies globally.
Stewart Tepper, MD, discusses his approach to integrating neuromodulation devices into patients' migraine treatment plans, how they work in conjunction with other therapies, and advice for clinicians seeking to incorporate them into their...
Stewart Tepper, MD, discusses his approach to integrating neuromodulation devices into patients' migraine treatment plans, how they work in conjunction with other therapies, and advice for clinicians seeking to incorporate them into their...
In this Q&A, Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research (CORe) Unite, University of Melbourne, shares insights a study recently published in Neurology.
In this Q&A, Tomas Kalincik, MD, PhD, Dame Kate Campbell Professorial Fellow, head of the Clinical Outcomes Research (CORe) Unite, University of Melbourne, shares insights a study recently published in Neurology.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Treatment outcome prediction models for patients with newly diagnosed epilepsy have a universally high risk of bias, researchers reported in a systematic review of nearly 50 such models published in the journal Epilepsia.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Tavapadon, an investigational D1/D5 dopamine receptor partial agonist for Parkinson disease (PD), met both the primary and secondary endpoints in the phase 3 TEMPO-1 clinical trial.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click